Integrated network pharmacology to investigate the mechanism of Salvia miltiorrhiza Bunge in the treatment of myocardial infarction
Journal of Cellular and Molecular Medicine · 2023-11 · 27 (22) · 3514-3525
DOI: 10.1111/jcmm.17932 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 29.08.2023. Verfasst von Xueying Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, China. Hauptthemen laut MEDLINE: Salvia miltiorrhiza, Myocardial Infarction, Drugs, Chinese Herbal. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Salvia miltiorrhiza Bunge is a natural drug for treating myocardial infarction (MI). However, the targets and mechanisms of S. miltiorrhiza Bunge in the treatment of MI are yet to be elucidated. Traditional Chinese medicine systems pharmacology (TCMSP) data were used to screen out chemical constituents, and UniProt was used to predict relevant targets. Disease targets were obtained from the Online Mendelian Inheritance in Man and GeneCards databases. We used the STRING platform to build a protein–protein interaction network and used Cytoscape_v3.8.1 software to make a Drug–Ingredients–Gene Symbols–Disease network map. The Metascape database was used to perform gene ontology and Kyoto Encyclopaedia of Genes and Genomes (KEGG) enrichment analyses for drug–disease overlapping gene symbols. The targets identified by network pharmacology were further verified by in vitro and in vivo experiments. Seventy‐five active components of S. miltiorrhiza Bunge were obtained from the TCMSP database, while 370 disease targets and 29 cross‐targets were obtained from the Genecards database. The KEGG pathway enrichment results suggested that the mechanism of S. miltiorrhiza Bunge in the treatment of MI was significantly related to the VEGF signalling pathway. In vitro and in vivo experiments were used to evaluate the reliability of some important active ingredients and targets. S. miltiorrhiza Bunge alleviated the damage to cardiac function, attenuated myocardial fibrosis and protected endothelial cell function by increasing the expression of TGF‐β and VEGFA. S. miltiorrhiza Bunge showed the therapeutic effect of MI by promoting the expression of VEGFA signalling pathway, providing a reliable basis for exploring herbal treatment of MI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, China.
- First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China.
- Innovative Institute of Chinese Medicine and Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, China.
ORCID-Profile: Chao Li
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Huang, X., Zhang, M., Song, Y., Sun, B., Lin, L., Song, X., & Li, C. (2023). Integrated network pharmacology to investigate the mechanism of Salvia miltiorrhiza Bunge in the treatment of myocardial infarction. Journal of Cellular and Molecular Medicine, 27(22), 3514-3525. https://doi.org/10.1111/jcmm.17932
Vancouver
Huang X, Zhang M, Song Y, Sun B, Lin L, Song X, et al. Integrated network pharmacology to investigate the mechanism of Salvia miltiorrhiza Bunge in the treatment of myocardial infarction. Journal of Cellular and Molecular Medicine. 2023;27(22):3514-3525. doi:10.1111/jcmm.17932
BibTeX
@article{Huang2023,
author = {Huang, Xueying and Zhang, Muxin and Song, Yu and Sun, Bowen and Lin, Lin and Song, Xiaoli and Li, Chao},
title = {Integrated network pharmacology to investigate the mechanism of Salvia miltiorrhiza Bunge in the treatment of myocardial infarction},
journal = {Journal of Cellular and Molecular Medicine},
year = {2023},
volume = {27},
number = {22},
pages = {3514--3525},
doi = {10.1111/jcmm.17932}
}
EUVIMED